research chemical comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Updated 2025-12-07. Numbers and descriptions here follow the published literature rather than marketing material.
Most published findings come from rodent models, where the peptide has been examined in wound-healing, gastrointestinal-lesion, tendon, and vascular-injury preparations. A smaller number of early human studies have been reported, chiefly in inflammatory bowel conditions, but the public record is short and has not led to marketing approval in the United States or the European Union. Reviewers therefore classify the compound as investigational, and whether animal results carry over to people remains an open question rather than a settled one.
Outside laboratory supply channels, the peptide is sold as a research chemical, a category that carries no requirement to demonstrate purity, identity, or freedom from contamination. Because it is not an approved medicine, products labeled BPC-157 sit in a regulatory gap in many countries, and actual content may differ from the label. Sports organizations list it among prohibited substances, so its presence in an athlete's sample can produce a doping finding regardless of how the material was obtained.
Identity and purity are established with complementary methods rather than one test. Reverse-phase high-performance liquid chromatography separates the main peak from deletion sequences and oxidized variants, and its area percentage is the usual purity figure. Mass spectrometry confirms the expected molecular mass and can flag truncations or modifications that chromatography alone might miss. Amino acid analysis and peptide mapping add sequence-level confirmation, while residual counter-ion and water content are measured separately.
A freeze-dried sample is generally the most stable form and is commonly held at minus twenty degrees Celsius or lower for long-term keeping, with brief transfers at room temperature. The solid is hygroscopic, so vials are warmed to ambient temperature before opening to prevent condensation from degrading the contents. Light exposure and repeated temperature cycling are both avoided in routine handling. Storage over a desiccant is a common laboratory practice that limits moisture uptake during repeated access.
Once dissolved, the material is considerably less stable than the dry solid. Aqueous solutions are usually kept cold and used within a short window, and neutral or mildly acidic buffers are preferred over strongly alkaline conditions. Freeze-thaw cycles promote aggregation and loss of material to container surfaces, so dividing a batch into single-use aliquots is standard. Adsorption to plastic and glass can lower the measured concentration, meaning solution strength may need rechecking before an experiment.
| Property | Value | Notes |
|---|---|---|
| Origin | Fragment of a protein found in human gastric juice | Sequence corresponds to a fifteen-residue portion of the parent protein |
| Sequence | GEPPPGKPADDAGLV | Single linear chain, fifteen amino acids |
| Reported molecular weight | About 1419 daltons | Value quoted consistently in supplier and review literature |
| Regulatory status | Not an approved human medicine in the US or EU | Handled and sold as a research chemical |
| Sports status | Listed as prohibited | Falls under non-approved-substance categories in anti-doping codes |
Doses in the literature are usually expressed in micrograms or nanograms per kilogram of body weight. Investigators have administered the peptide by several routes, including injection and oral delivery, depending on the question asked. Route and dose vary widely across studies, which complicates direct comparison of results. Many papers report effects at low doses, but the absence of a standardized protocol limits generalization. Reporting practice differs between research groups.
Some properties, such as the peptide's sequence and molecular mass, are firmly established. Other claims, particularly about mechanism and clinical benefit, remain open questions. Proposed mechanisms include effects on nitric oxide signaling and on cell migration, but these are hypotheses supported by limited evidence. Reviewers often note that the field lacks large controlled human trials. Positive animal findings are best treated as signals for further study rather than as settled conclusions.
BPC-157 is a synthetic peptide built from fifteen amino acids, referred to in the literature as a pentadecapeptide. Its sequence was derived from a larger protein found in human gastric juice, commonly called body protection compound. Researchers first described the fragment in the early 1990s and named it after the parent protein plus a numeric identifier. The peptide does not correspond to a single marketed medicine; it is primarily a laboratory research material. Suppliers distribute it as a lyophilized powder intended for experimental use.
Published work on BPC-157 spans several decades and covers a wide range of experimental models. Much of the early literature reports outcomes in animal studies involving induced injury to the gastrointestinal tract, tendons, and other tissues. The volume of preclinical reports is large, while controlled human trials remain scarce. This imbalance is a recurring point of discussion, because animal findings do not automatically translate into human effects. Reviews often note that study designs differ substantially across laboratories.
=== Nervous system === People with amyloidosis may have central nervous system involvement, along with peripheral involvement which causes sensory and autonomic neuropathies. Sensory neuropathy develops in a symmetrical pattern and progresses in a distal to proximal manner. Autonomic neuropathy can present as orthostatic hypotension but may manifest more gradually with nonspecific gastrointestinal symptoms like constipation, nausea, or early satiety. Amyloidosis of the central nervous system can have more severe and systemic presentations that may include life-threatening arrhythmias, cardiac failure, malnutrition, infection, or death. Neuropathic presentation can depend on the etiology of amyloidosis. People with amyloidosis may experience dysfunction in various organ systems depending on the location and extent of nervous system involvement. For example, peripheral neuropathy can cause erectile dysfunction, incontinence and constipation, pupillary dysfunction, and sensory loss depending on the distribution of amyloidosis along different peripheral nerves.
Brorphine is a piperidine-based opioid analgesic compound. Brorphine was originally described in a 2018 paper investigating functionally biased opioid compounds, with the intention of finding safer analgesics that produce less respiratory depression than typical opioids. Brorphine was originally reported to be highly biased, with an EC50 of 4.8nM for GTPγS binding and 182nM for β-arrestin recruitment, however a more recent study found no significant bias for any of the compounds tested, including brorphine. Its safety profile in any animal model has never been established. In a study involving human lymphoblastoid TK6 cells looking at the possible mutagenic effect of several orphine analogues, brophine was shown to have a marked cytostatic effect but no mutagenic properties. Despite the lack of safety information on the compound, brorphine has been sold as a designer drug since mid-2019, initially being identified in the US Midwest, though it has since been found in 2020 in Belgium. It is related in chemical structure to compounds such as benzylfentanyl and bezitramide, though it is sufficiently structurally distinct to fall outside the formal definition of a "fentanyl analogue" in jurisdictions such as the US and New Zealand which have Markush structure controls over this family of drugs. Despite its name, it is not a structural analog of morphine. Brorphine was first identified in the U.S.
Primarily through the suspension of Qatari liquefied natural gas (LNG) and the closure of the Strait of Hormuz, several publications including the BBC, PBS, Deutsche Welle, Euronews, Financial Times and Bruegel, along with banks and think tanks, have projected that the continent will enter an energy crisis in 2026 similar to the 2022 energy crisis that followed the War in Ukraine. The conflict coincided with historically low European gas storage levels – estimated at just 30% capacity following a harsh 2025–2026 winter – causing Dutch TTF gas benchmarks to nearly double to over €60/MWh by mid-March. On 26 March, the European Commission advised its member states to fill their gas storages early to avoid price spikes later in the year.
In addition, Greek authorities seized a 7,000 square-metre plot of land on Paros, Greece in the Cyclades islands, which had been purchased jointly by Kaili and Giorgi. As the European Parliament convened for the first time following the scandal, on 13 December 2022, at its seat in Strasbourg, France, the offices of MEP Pietro Bartolo and Parliamentary official Mychelle Rieu were sealed by investigators. On 15 December, the European Public Prosecutor's Office (EPPO) requested that the European Parliament lift the parliamentary immunity of Eva Kaili and her fellow Greek MEP Maria Spyraki. The EPPO explained that the request was based on an investigative report from the European Anti-Fraud Office (OLAF), regarding raised "suspicion of fraud detrimental to the EU budget, in relation to the management of the parliamentary allowance." The request particularly pertained to funds paid to parliamentary assistants. On 2 January 2023, Belgian investigators submitted a request to the European Parliament to strip MEPs Marc Tarabella and Andrea Cozzolino of their parliamentary immunity. A hearing of the Parliament's Legal Affairs Committee was scheduled during the parliamentary sitting in Strasbourg on 16 January, allowing the accused MEPs to present their defence. The parties of both Tarabella and Cozzolino expressed their support for President Metsola's requests to assist the European Public Prosecutor's Office in the investigations and agreed to vote in favour of waiving their immunity. On 2 February, the European Parliament approved the request to lift their immunity.
Domino's Pizza Israel was founded in 1990, and opened their first branch in 1993. They are operated by Elgad Pizza. As of August 2014, there are 33 branches throughout the state. There are four kosher franchises. The rights to own, operate, and franchise branches of the chain in Australia, New Zealand, France, Belgium, the Netherlands, Monaco, Luxembourg, Germany, Japan, Malaysia, Singapore, Taiwan and Cambodia are currently owned by Australian Domino's Pizza Enterprises, having bought the master franchises from the parent company in 1993 (Australian and New Zealand franchises). The Australian company also acquired several European and Asian franchises between 2013 and 2022. It acquired the Danish operations in 2019 but liquidated them in 2023. The master franchises for the UK and Ireland were purchased in 1993 by the British publicly listed Domino's Pizza Group (DPG), which acquired the master franchise for Germany in 2011, and Switzerland, Liechtenstein, and Luxembourg in August 2012 by buying the Swiss master franchise holder, with an option to acquire the Austrian master franchise as well. DPG opened its first Swedish location near the Mobilia shopping mall in Malmö in December 2016; three years later, in 2019, they announced that they would be selling all of their current businesses in the country. In Latin America, the first franchise was opened in 1988 in Colombia. During the next years, Domino's Pizza started operations in Mexico, Guatemala (1989), Chile (1991), Venezuela (1992), Dominican Republic (1993), Ecuador and Peru (1995).
Sources: en.wikipedia.org
Come What(ever) May sold over 80,000 copies in its first week and entered the Billboard 200 chart in the United States at #4, and went on to be certified platinum in the United States, Canada and New Zealand, and gold in the United Kingdom and Australia. In 2007, the single "30/30-150" was nominated for Best Metal Performance at the 49th Grammy Awards.
The daughter nuclide of a decay event may also be unstable (radioactive). In this case, it too will decay, producing radiation. The resulting second daughter nuclide may also be radioactive. This can lead to a sequence of several decay events called a decay chain (see this article for specific details of important natural decay chains). Eventually, a stable nuclide is produced. Any decay daughters that are the result of an alpha decay will also result in helium atoms being created. Some radionuclides may have several different paths of decay. For example, 35.94(6)% of bismuth-212 decays, through alpha-emission, to thallium-208 while 64.06(6)% of bismuth-212 decays, through beta-emission, to polonium-212. Both thallium-208 and polonium-212 are radioactive daughter products of bismuth-212, and both decay directly to stable lead-208.
Industrial production of ethoxylates is realized by a direct reaction of higher alcohols, acids, or amines with ethylene oxide in the presence of an alkaline catalyst at a temperature of 120–180 °C (250–360 °F). Modern plants producing ethoxylates are usually based on the BUSS LOOP reactors technology, which is based on a three-stage continuous process. In the first stage, the initiator or catalyst of the reaction and the feedstock are fed into the container, where they are mixed, heated, and vacuum dried. Then reaction is carried out in a special insulated reactor in an inert atmosphere (nitrogen) to prevent a possible explosion of ethylene oxide. Finally, the reaction mixture is neutralized, degassed, and purified.
=== CorBLOSUM === A 2016 paper finds further errors in the original code not addressed by the 2008 RBLOSUM correction. The corrected version from this paper, CorBLOSUM, manages to be more effective than BLOSUM at similarity search in about 75% of cases.
Sources: en.wikipedia.org
It is not approved for human use in the United States or the European Union. Clinical material has been studied in a small number of early trials, mainly for inflammatory bowel conditions, and the compound remains investigational. Regulators treat marketed products as unapproved rather than as authorized drugs.
The peptide was named after a protein fraction found in human gastric juice, and the shorter form was called body protection compound. That phrase was shortened to the abbreviation BPC. The number 157 refers to a laboratory designation used in the original isolation work.
Its sequence corresponds to a segment of a protein present in gastric secretions, but the material supplied for research is made synthetically. No commercial product is purified from human or animal tissue. The synthetic route is used because it gives a defined chain length and a reproducible sequence.
Low temperature slows the chemical reactions, such as oxidation and hydrolysis, that break down a peptide chain. Water and oxygen are the main drivers of degradation, so a cold and dry environment extends usable life. Actual shelf life depends on the batch, the salt form, and the container.